Drug intelligence / Profile preview

cibisatamab + atezolizumab + obinutuzumab

Development stage: Discontinued
Lead developer: Roche
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This combination regimen consists of **cibisatamab**, a bispecific monoclonal antibody targeting carcinoembryonic antigen (CEACAM5) on tumor cells and CD3 epsilon chain on T cells to mediate T-cell–directed cytotoxicity; **atezolizumab**, an anti–PD-L1 checkpoint inhibitor that blocks the interaction of programmed death-ligand 1 (PD-L1) with its receptors PD-1 and B7.1 to enhance anti-tumor immunity; and **obinutuzumab**, a glycoengineered humanized anti-CD20 monoclonal antibody that depletes B cells and is used as pretreatment to reduce anti-drug antibody (ADA) development against cibisatamab. The regimen was designed for use in metastatic, microsatellite-stable (MSS) colorectal adenocarcinoma with high CEACAM5 expression after progression on standard chemotherapies[1][2][3][5].

Other names: Tecentriq (atezolizumab)Gazyva (obinutuzumab)

Targets

CD20 (B-lymphocyte antigen CD20)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)CD274 (Programmed cell death protein 1 ligand 1)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on cibisatamab + atezolizumab + obinutuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cibisatamab + atezolizumab + obinutuzumab.

Explore the full profile